RP-HPLC–UV method for the quantification of propranolol in rat's serum and krebs buffer using one-step protein precipitation

• Autorzy: Al Shaker H. , Qinna Nidal A. , Hroub H. , Omari M. M. H. , Adnan A.

Identyfikatory

DOI

10.1556/1326.2017.00018

• Języki publikacji: EN

Abstrakty

EN

Krebs buffer is considered one of the most used physiological buffers in biomedical research. In the current work, a rapid reversed-phase high-performance liquid chromatographic (RP-HPLC) method with ultraviolet (UV) detection at 214 nm was developed and validated according to European Medicines Evaluation Agency (EMEA) guidelines for the determination and quantification of propranolol in Sprague–Dawley rat's serum and in Krebs buffer. This method can be applied for both in vivo and in vitro studies with short run time of 7.0 min . Isocratic elution with a flow rate of 1.0 mL/min was employed. BDS Hypersil C-18 column (150 mm × 4.6 mm and 5 μm) was used to obtain satisfactory resolution. The mobile phase used contained a mixture of acetonitrile, methanol, and triethylammonium phosphate solution (15.0:32.5:52.5, v/v). Best separation between propranolol and the internal standard (I. S.) sildenafil was obtained at 4.2 and 5.5 min, respectively. Propranolol was linear over a concentration range of 50.00–3000 ng/mL with acceptable accuracy, and intra- and inter-day precision. Dilution integrity was assessed and was found to be within the acceptable range for both serum and Krebs buffer. Sample stability tests were studied at different storage conditions, and all the analytes were found to be stable. The mean percentage of recovery of propranolol was found to be 97.06% and 98.57% for serum and Krebs buffer, respective.

Słowa kluczowe

EN

Propranolol; RP-HPLC-UV; serum; protein precipitation; method development; validation

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2018
• Tom: Vol. 30, no. 3
• Strony: 147--152
• Opis fizyczny: Bibliogr. 27 poz., rys.

Twórcy

autor

Al Shaker H.

• Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan

autor

Qinna Nidal A.

• Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan

autor

Hroub H.

• Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan

autor

Omari M. M. H.

• Research and Innovation Centre, The Jordanian Pharmaceutical Manufacturing Company (PLC), Naor 11710, Jordan

autor

Adnan A.

• Research and Innovation Centre, The Jordanian Pharmaceutical Manufacturing Company (PLC), Naor 11710, Jordan

Bibliografia

• [1] Salman, S. A.; Sulaiman, S. A.; Ismail, Z.; Gan, S. H. Toxicol. Mech. Methods 2010, 20, 137.
• [2] Cole, S. W.; Sood, A. K. Clin. Cancer Res. 2012, 18, 1201.
• [3] Priviero, F. B.; Teixeira, C. E.; Claudino, M. A.; De Nucci, G.; Zanesco, A.; Antunes, E. Eur. J. Pharmacol. 2007, 571, 189.
• [4] Hebb, A. R.; Godwin, T. F.; Gunn, R. W. Can. Med. Assoc. J. 1968, 98, 246.
• [5] Bruns, L. A.; Canter, C. E. Paediatr Drugs 2002, 4, 771.
• [6] WHO, , World health organization model list of essential medicines: 17th list. Available at http://apps.who.int/iris/bitstream/10665/70640/1/a95053_eng.pdf, 2011. Access date: 1 October 2015.
• [7] Hackett, L.; Dusci, L. Clin. Toxicol. 1979, 15, 63.
• [8] Semple, H. A.; Xia, F. J. Chromatogr. B Biomed. Sci. Appl. 1994, 655, 293.
• [9] Rekhi, G. S.; Jambhekar, S. S.; Souney, P. F.; Williams, D. A. J. Pharm. Biomed. Anal. 1995, 13, 1499.
• [10] Braza, A. J.; Modamio, P.; Mariño, E. L. J. Chromatogr. B Biomed. Sci. Appl. 2000, 738, 225.
• [11] Zhanga, J.; Dinga, L.; Wenb, A.; Wua, F.; Suna, L.; Yangb, L. Asian J. Pharm. Sci. 2009, 4, 169.
• [12] Li, S.; Liu, G.; Jia, J.; Liu, Y.; Pan, C.; Yu, C.; Cai, Y.; Ren, J. J. Chromatogr. B 2007, 847, 174.
• [13] Umezawa, H.; Lee, X. P.; Arima, Y.; Hasegawa, C.; Izawa, H.; Kumazawa, T.; Sato, K. Biomed. Chromatogr. 2008, 22, 702.
• [14] Delamoye, M.; Duverneuil, C.; Paraire, F.; de Mazancourt, P.; Alvarez, J.-C. Forensic Sci. Int. 2004, 141, 23.
• [15] El-Saharty, Y. J. Pharm. Biomed. Anal. 2003, 33, 699.
• [16] Xiao, S.; Wei, G.; Guo, H.; Liu, H.; Liu, C. Asian Journal of Pharmacodynamics and Pharmacokinetics 2008, 8, 153.
• [17] Kim, H.; Hong, J.; Park, M.; Kang, J.; Lee, M. Biomed. Chromatogr. 2001, 15, 539.
• [18] Gaginella, T. S. Handbook of Methods in Gastrointestinal Pharmacology CRC Press, Informa group, London, 1995.
• [19] Bailey, L. E.; Ong, S. D. J. Pharmacol. Methods 1978, 1, 171.
• [20] EMEA, European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) 2012.
• [21] Custodio, J. M.; Wu, C.-Y.; Benet, L. Z. Adv. Drug Deliv. Rev. 2008, 60, 717.
• [22] Wu, S. T.; Chang, Y. P.; Gee, W. L.; Benet, L. Z.; Lin, E. T. J. Chromatogr. B Biomed. Sci. Appl. 1997, 692, 133.
• [23] Christie, W. W. Advances in Lipid Methodology vol. 4, Woodhead Publishing Limited, UK, 2012, 239.
• [24] Srikanth, M.; Ram, B. J.; Sunil, S.; Rao, N. S.; Murthy, K. R. Journal of Scientific and industrial Research 2012, 71, 120.
• [25] Kupiec, T. Int. J. Pharm. Compd. 2004, 8, 223.
• [26] McMaster, M. HPLC: a practical user's guide John Wiley & Sons, Hoboken, New Jersey, 2007.
• [27] Zhou, M. Regulated Bioanalytical Laboratories: Technical and Regulatory Aspects from Global Perspectives John Wiley & Sons, Hoboken, New Jersey, 2011.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).